1. Partners in care to Improve Quality of Life Abboud Bejjani Vice President AbbVie Biopharmaceutical
Cairo March 13/2014

2. Who I am? Consulting 15 Years! Degree… Vice President
Middle East, Africa & Pakistan
Consulting
15 Years!

3. AbbVie… Who We are?
A leading global biopharmaceutical company one year old, but carrying 120 years history in research.
AbbVie aspires to contribute to Healthcare Sustainability via Innovative Medicines and New Healthcare Solutions.
(Chicago Based company)

4. Responsibly active member of the community
AbbVie Way!
Leading biopharmaceutical company in the life sciences industry that fosters pharma innovation & competitiveness
a long-term, reliable Partner and a key contributor to the economy and healthcare sustainability
Responsibly active member of the community

5. AbbVie Part of the Innovative Biopharmaceutical Industry
The innovative biopharmaceutical industry represents global leading pharmaceutical research and biotechnology companies
Our companies are devoted to discovering new medicines that allow patients to live longer, healthier, and more productive lives
In 2009, the biopharmaceutical sector invested approximately $65.3 billion in research and development

6. Biopharmaceutical Companies’ Investment in R&D Increasing Steadily“
Total Biopharmaceutical Company R&D and
PhRMA Member R&D: 1995–20081
The pharmaceutical industry is one of the most research-intensive industries in the United States. Pharmaceutical firms invest as much as five times more in research and development, relative to their sales, than the average U.S. manufacturing firm.2
— Congressional Budget Office “
Sources: 1Burrill & Company, analysis for PhRMA, 2005–2009; Pharmaceutical Research and Manufacturers of America, PhRMA Annual Member Survey (Washington, DC: PhRMA, ); 2CBO, Research and Development in the Pharmaceutical Industry, 2006. 6 6

7. AbbVie Leading Therapeutical Areas & Research Focus
Immunology
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriasis
Crohn’s Disease
Neonatology (preterm babies)
Anesthesia
Antiviral (HIV/HCV)
Renal Disease
Central Nervous System
Oncology

8. Can we Partner ? AbbVie & The Arab World Long Term Relation Ship
Over 60 years of PartnerShip!
FOCUS
Partners in care to Improve Quality of Life

9. Health Authorities’ Objectives
How
Consequence
By Improving Longevity and Quality of Life
Higher Quality Care
Manage rising Healthcare costs
By Widening Access
To Care

10. How we can help? Technology and knowledge transfer
Improve patient access to innovative medicines and as results improve patient outcomes
Improve efficiency of healthcare delivery
Anticipate in boosting the economy by local investments
Technology and knowledge transfer
Create high quality jobs

11. Improve patient access to innovative medicines and as results improve patient outcomes
Prescription medicines play a major role in saving and improving lives
Over the last 25 years, prescription medicines have significantly reduced deaths from major diseases such as heart disease, several cancers, and HIV /AIDS
Improved the quality of lives of people suffering from conditions such as arthritis disease. Currently we are talking about full remission from Many Immune Diseases such as Crohn’s, Rheumatoid Arthritis, Psoriasis, Parkinson, needless to mention the prematurity solutions for babies…etc…
Recent advances include a new generation of personalized medicines, treatment for some rare diseases and cure for infections like Hepatitis C.

12. Major Advances in Treatment and Prevention
Since 1980 life expectancy for cancer patients has increased by 3 years. Research finds that medicines alone account for 50-60% of survival increases.
Thanks in part to new medicines, heart failure and heart attack deaths fell by 45% in just the last decade.
Within three years of introduction of the first antiretroviral treatments, HIV/AIDS deaths dropped by nearly 70%.
“The rapid increases that have been observed in drug-related R&D spending have been accompanied by major therapeutic gains in available drug treatments.”
CBO, 2006
E. Sun, et al., “The Determinants of Recent Gains in Cancer Survival: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database,” Journal of Clinical Oncology, May 2008 Suppl (Abstract 6616).
F. Lichtenberg, “The Expanding Pharmaceutical Arsenal in the War on Cancer,” NBER Working Paper 10328, February, 2004.
K. A. Fox, et al., “Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, ,” Journal of the American Medical Association (JAMA) 297, no. 17 (2007):
CASCADE Collaboration, “Determinants of Survival Following HIV-1 Seroconversion After Introduction of HAART,” The Lancet 362 (2003): 12

13. HIV/AIDS: Decline in Death rates

14. U.S. Life Expectancy

15. How we can help? Technology and knowledge transfer
Improve patient access to innovative medicines and as results improve patient outcomes
Improve efficiency of healthcare delivery
Anticipate in boosting the economy by local investments
Technology and knowledge transfer
Create high quality jobs

16. Improving Efficiency of Healthcare Delivery
Efficient management of Non Communicable Diseases through :
Health education
Disease management programs
Patient screening programs
Eradication of communicable diseases
Early introduction of innovative therapeutic options
Continuous medical education of HCP
Training of healthcare professionals

17. Some Real Life Examples of Health Education– IMID Congress
IMID – Immune Mediated Inflammatory Disorders Congress 5% -7% MEA population is afflicted
Treated and managed by multi-specialists like Rheumatologists, Dermatologists, Gastroenterologists, Ophthalmologists and Internists who have little time and opportunity to communicate with each other.
IMID Congress created a multispecialty platform to bring these specialists together to discuss the latest developments and research to achieve improved patient outcomes. Result: Increased referrals of patients across the specialties that facilitates better co-management of patients.

18. Improving Efficiency of Healthcare Delivery
Efficient management of Non Communicable Diseases through :
Health education
Disease management programs
Patient screening programs
Eradication of communicable diseases
Early introduction of innovative therapeutic options
Continuous medical education of HCP
Training of healthcare professionals
Public Awareness

19. Some Real Life Examples of what we did – Academy of Imaging
AbbVie partnered with GENERAL Electric to support continuous education of Rheumatologists who were interested in learning ultrasound of the joints. This education was the first of its kind in the MEA and helped to improve the standard of care of the RA patients and support the physician in diagnosis and monitoring of the disease.
Result: Rheumatologists started using US in practice and ultrasound became increasingly recognized as a standard tool for diagnosing and treating the aggressive disease early.

20. Improving Efficiency of Healthcare Delivery
Efficient management of Non Communicable Diseases through :
Health education
Disease management programs
Patient screening programs
Eradication of communicable diseases
Early introduction of innovative therapeutic options
Continuous medical education of HCP
Training of healthcare professionals
Public Awareness

21. Some Real Life Examples of what we did – Patient Support Program
Patient Support Specialists (trained physicians and pharmacists by qualification) educate patients on disease understanding and elevate awareness on possible detrimental outcomes if left untreated.
In addition:
Organize patients’ days whereby consultants are
invited to educate patients
Advise patients to follow up with Physiotherapists
Organize meetings of patients with Nutritionists to learn about optimal diet regime.
Facilitate appointment with Psychiatrists for the depressed Ps patients if needed
The program is endorsed by MOH and Health Authorities
Received endorsement of the Her Royal Highness Princess Oraib Al Saud (daughter of HH Saudi King) to endorse a valuable program aimed to raise prematurity awareness and to call for action to set the healthcare standards of Neonatology in Saudi.
The program is supported by many other corporate partners.

22. How we can help? Technology and knowledge transfer
Improve patient access to innovative medicines and as results improve patient outcomes
Improve efficiency of healthcare delivery
Anticipate in boosting the economy by local investments
Technology and knowledge transfer
Create high quality jobs

23. Health Authorities’ Objectives
How
Consequence
Improve Longevity and Quality of Life
Higher Quality Care
Manage rising Healthcare costs
Wider Access
To Care

24. How we can help?

25. PPP: Elements of Success !
Open Dialogue
Transparency
Trust

26. What is required from our side!
Better Understanding of your challenges
More discussion
Don’t be afraid!
Open Dialogue
Transparency
Trust
Show what we do

27. What we like you to do! Better Understanding of our challenges
Open hears for Pharma Economics Discussion
Open Dialogue
Transparency
Trust
Pharma As a Cost component of Health Bill

28. What we like you to do! Better Understanding of our challenges
Open hears for Pharma Economics Discussion
Open Dialogue
Transparency
Trust
Pharma As a Cost component of Health Bill

29. Industry Concern : Valuable But Vulnerable
Limitless
Challenge
Opportunities
Growing 29

30. Developing a new medicine is lengthy, risky, and costly.
DO YOU KNOW??
Developing a new medicine is lengthy, risky, and costly.
New drug development takes an average of 10–15 years, and costs approx. US $1.3 billion.
INDEFINITE
Drug Discovery
Preclinical
Clinical Trials
FDA Review
Scale-Up to Mfg.
Post-Marketing Surveillance
ONE FDA-APPROVED DRUG
0.5 – 2 YEARS
6 – 7 YEARS
3 – 6 YEARS
NUMBER OF VOLUNTEERS
PHASE 1
PHASE 2
PHASE 3 5
250
~ 5,000 – 10,000
COMPOUNDS
PRE-DISCOVERY
20–100
100–500
1,000–5,000
IND SUBMITTED
NDA SUBMITTED 30
Sources: Drug Discovery and Development: Understanding the R&D Process, 30

31. Cost to Develop One New Drug
Do you know??
Cost to Develop One New Drug
Billions
J. Dimasi, “Measuring Trends in the Development of New Drugs: Time, Costs, Risks and Returns,” Presentation to the SLA Pharmaceutical & Health Technology Division Spring Meeting, 2007; Tufts Center for the Study of Drug Development, “Growing Protocol Design Complexity Stresses Investigators, Volunteers,” Impact Report, 2008.
Tufts Center for the Study of Drug Development, “Growing Protocol Design Complexity Stresses Investigators, Volunteers,” Impact Report, 2008.
J. Dimasi and H. Grabowski, “The Cost of Biopharmaceutical R&D: Is Biotech Different?,” Managerial and Decision Economics, 2007; J. Dimasi et al., “The Price of Innovation: New Estimates of Drug Development Costs,” Journal of Health Economics, 2003. 31 31

32. Successfully Approved Commercial Medecines

33. What we like you to do! Better Understanding of our challenges
Open hears for Pharma Economics Discussion
Open Dialogue
Transparency
Trust
Pharma As a Cost component of Health Bill

34. Medicines can Result in Extraordinary Savings for Patients and Health Systems
Medicines can reduce health costs by preventing and managing disease
In the U.S., for example, each prescription saves US $57 in avoidable hospital costs.
Diabetes: $1 more spent on diabetes medicines = US $7.10 less spent on other services.
High Blood Pressure: In 2002, antihypertensives prevented 833,000 stroke and heart attack hospitalizations, saving US $16.5 billion in medical costs.
Asthma: A 10% increase in adherence to asthma medicines in elderly patients leads to a 5% decrease in total annual medical spending.
Sources: Sources: B.C. Stuart, et al. ”Assessing the Impact of Drug Use on Hospital Costs.”Health Services Research, February 2009; M.C. Sokol, K.A. McGuigan, R.R. Verbrugge, R.S. Epstein, “Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost,” Medical Care, 43 (2005): 6, ; D. Cutler, et al., “The Value of Antihypertensive Drugs: A Perspective on Medical Innovation,” Health Affairs, January/February, 2007; B. Briesacher, et al. “Consequences of Poor Compliance with Biphosphonates,” Bone, 2007.
R. Balkrishnan, et al., “Self-Reported Health Status, Prophylactic Medication Use, and Healthcare Costs in Older Adults with Asthma,: Journal of the American Geriatric Society, 2002. 34

35. What we like you to do! Better Understanding of our challenges
Open hears for Pharma Economics Discussion
Open Dialogue
Transparency
Trust
Pharma As a Cost component of Health Bill

36. Medicines and Health Spending Growth

37. We need Common understanding!
Common Interest and Better understanding of each other needs
Open Dialogue
Transparency
Trust

38. Improving Patients’ Health and Quality of Life
“New drugs allow children with rheumatoid arthritis to walk and to go to school. New drugs shrink cancerous tumors and they control the advance of HIV. They prevent or halt heart disease, slow the progression of multiple sclerosis, and cure infectious diseases.” 13
—Mark B. McClellan, M.D., Ph.D., Then-FDA Commissioner,
September 2003
Innovative medicines not only extend life but also make life itself better
for patients. New medicines can improve quality of life for patients
suffering from long-term illnesses or help patients remain independent by
preventing disability. Patients’ lives are often improved by medicines
because the medicines can avert complications or limit the severity of a
sickness. For example:
• Increasingly, researchers and clinicians are turning their attention to
targeted therapies, which attack cancer cells while avoiding healthy
ones. These medicines are generally given in the form of pills rather
than as intravenous (IV) drugs. Because they do not kill healthy cells,
they are capable of fighting cancer with fewer side effects such as
nausea and hair loss.
• One recent study found that inner-city children who had asthma, but
were enrolled in a comprehensive disease management program that
included appropriate medications, experienced significant quality of
life improvements. As their symptoms decreased and their capacity for
activity rose, they reported greater emotional well-being.24

39. Partners in care to Improve Quality of Life
YES WE ARE PARTNERS!!!
Partners in care to Improve Quality of Life

40. THANK YOU